Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias-Reference-Cited by-同舟云学术

Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias

Published:2023-05-18 Issue:7 Volume:37 Page:1464-1473
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Nikitin Eugene^ORCID,Kislova Maria^ORCID,Morozov Dmitry^ORCID,Belyakova Vera^ORCID,Suvorova Anna^ORCID,Sveshnikova Julia^ORCID,Vyscub Galina^ORCID,Matveeva Irina^ORCID,Shirokova Maria^ORCID,Shipaeva Anna^ORCID,Klitochenko Tatyana^ORCID,Makarovskaya Polina^ORCID,Dmitrieva Elena^ORCID,Biderman Bella^ORCID,Sudarikov Andrei^ORCID,Obukhova Tatyana^ORCID,Samoilova Olga,Kaplanov Kamil,Konstantinova Tatyana,Mayorova Olga^ORCID,Poddubnaya Irina,Ptushkin Vadim^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-023-01891-3.pdf

Reference50 articles.

1. Fattizzo B, Barcellini W. Autoimmune cytopenias in chronic lymphocytic leukemia: focus on molecular aspects. Front Oncol. 2019;9:1435.

2. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–60.

3. Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood. 2008;111:1820–6.

4. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl J Med. 2013;369:32–42.

5. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Peculiar CLL Case with Complex Chromosome 6 Rearrangements and Refinement of All Breakpoints at the Gene Level by Genomic Array: A Case Report;Journal of Clinical Medicine;2023-06-17